Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

PharmaShots Interview In Conversation with SOTIO’s CMO, Richard Sachse, Where he Shares Insights on New Interim Data presented in an Oral Presentation at AACR 2022 Annual Meeting
PharmaShots Interview: In Conversation with SOTIO’s CMO, Richard Sachse, Where he Shares Insights on New Interim Data presented in an Oral Presentation at AACR 2022 Annual Meeting
Shots: Richard spoke about the results from the Phase 1 AURELIO-03 study of IL-15 superagonist Richard also emphasized the clinical benefits of the IL-15 superagonist when combined with pembrolizumab The interview gives a profound understanding of the existing & developing cancer therapies as treatment options for solid tumors Smriti: Explain the details (MOA, ROA, formulations, etc.)…
June 22, 2022
PharmaShots Interview In Conversation with Cecelia’s CMO, Arnold Saperstein, Where he Shares Insights on Improving Outcomes for Children and Adolescents Living With Type 1 Diabetes (T1D)
PharmaShots Interview: In Conversation with Cecelia’s CMO, Arnold Saperstein, Where he Shares Insights on Improving Outcomes for Children and Adolescents Living With Type 1 Diabetes (T1D)
Shots: Arnold spoke about Cecelia Health’s collaboration with the UBMD Paediatrics for a clinical study to improve health outcomes for children and adolescents living with T1D Arnold also gave his views on how telehealth options can support the unmet needs of patients with T1D The interview provides a gist of the challenges of living with…
June 20, 2022
PharmaShots Interview In Conversation with Leonard A. Farber and James Welsh, Where they Share Insights on How Nanoparticle can Trigger an Immune Priming Effect
PharmaShots Interview: In Conversation with Leonard A. Farber and James Welsh, Where they Share Insights on How Nanoparticle can Trigger an Immune Priming Effect
Shots: Leonard spoke about the newly developed radiotherapy-activated nanoparticle and other cancer therapies developing in Nanobiotix’s pipeline James shared his views on the data presented at the 2022 Annual Meeting of the American Association of Cancer Research The interview provides a core understanding of Nanobiotix’s outlook to expand the utility of nanoparticles in cancer treatment…
June 15, 2022
PharmaShots Interview In Conversation with Portage’s CEO and Director, Dr. Ian Walters, Where he Shares Insights on Ongoing Clinical-Stage and Development Programs
PharmaShots Interview: In Conversation with Portage’s CEO and Director, Dr. Ian Walters, Where he Shares Insights on Ongoing Clinical-Stage and Development Programs
Shots: Ian spoke about the study design of the clinical trials of its lead iNKT agonists He also emphasized the advancement of novel immunotherapies through new collaborations  The interview provides a gist of Portage's development plan for its pipeline and various options to improve cancer treatment Smriti: Explain the details (MOA, ROA, formulations, etc.) of PORT-2 & PORT-3?…
June 8, 2022
PharmaShots Interview In Conversation with Cidara’s CEO, Dr.Jeff Stein, Where he Shares Insights on the IND acceptance by the FDA to Treat Influenza
PharmaShots Interview: In Conversation with Cidara’s CEO, Dr.Jeff Stein, Where he Shares Insights on the IND acceptance by the FDA to Treat Influenza
Shots: Jeff spoke about IND acceptance by the US FDA for its lead flu drug-Fc conjugate immunotherapy for the prevention and treatment of Influenza He also discussed Cidara’s collaboration with Janssen Pharmaceuticals to develop and commercialize Cidara’s DFCs The interview also emphasizes Cidara’s Cloudbreak platform to develop immunotherapeutic antivirals and treatment options for influenza Smriti:…
June 6, 2022
PharmaShots Interview In Conversation with Amolyt’s CEO, Thierry Abribat, Where he Shares Insights on Amolyt as a Key Player in Hypoparathyroidism Space
PharmaShots Interview: In Conversation with Amolyt’s CEO, Thierry Abribat, Where he Shares Insights on Amolyt as a Key Player in Hypoparathyroidism Space
Shots: Thierry spoke about the IND clearance of its lead candidate in hypoparathyroidism and the company’s clinical trial plans for rare endocrine and related diseases Thierry also communicated about the closing of funding Series B equity financing round The interview gives a deeper understanding of Hypoparathyroidism and its treatment options Smriti: What did this Investigational…
June 1, 2022
PharmaShots Interview In Conversation with Pyxis’ CMO Jay M. Feingold, Where he Shares Insights on the addition of In-Licensed & Internal IO Assets
PharmaShots Interview: In Conversation with Pyxis’ CMO Jay M. Feingold, Where he Shares Insights on the addition of In-Licensed & Internal IO Assets
Shots: Jay talked about the in-licensing of an IND-ready immuno-oncology (IO) candidate, anti-Siglec-15 Mab to the pipeline Jay also spoke about the company’s IO targets and other under development immunotherapies In addition, the interview provided the corporate and financial updates of the Pyxis Oncology Smriti: Can you tell us something about your in-licensed Mab anti-Siglec-15,…
May 31, 2022
PharmaShots Interview MindMed’s Robert Barrow Shares Insights on Study to show Key Differences Between LSD and Psilocybin
PharmaShots Interview: MindMed’s Robert Barrow Shares Insights on Study to show Key Differences Between LSD and Psilocybin
In an interview with PharmaShots, Robert Barrow, CEO at MindMed shared his views on the Study Acute Effects of Lysergic Acid Diethylamide vs. Psilocybin in Healthy Subjects Shots: Robert spoke about the data from the peer-reviewed publication of a study comparing the acute effects of LSD and psilocybin in healthy subjects Robert also emphasized the clinical results and significance of…
May 30, 2022
Load more